Biohaven acquires exclusive license for oral, brain-penetrant, dual tyk2/jak1 inhibitor for immune-mediated brain disorders

Novel first-in-class, brain-penetrant, dual inhibitor of tyk2/jak1 offers wide therapeutic index with tyk2 inhibition and high selectivity for jak1 inhibition without the severely limiting adverse class effects of jak2/jak3 inhibitors exclusive license covers global rights excluding china region biohaven anticipates initiating phase 1 clinical development in 2023 new haven, conn. , march 22, 2023 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking